Jazz Pharmaceuticals, maker of the blockbuster epilepsy drug Epidiolex, is acquiring Actio Biosciences and its lead drug in pivotal testing for a rare type of epilepsy with no FDA-approved treatments. It’s Jazz’s second epilepsy deal in the past year.
The post Jazz Pharma Expands Again in Epilepsy With $850M Actio Bio Acquisition appeared first on MedCity News.
